Focused On-demand Library for Eyes absent homolog 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q99504

UPID:

EYA3_HUMAN

Alternative names:

Alternative UPACC:

Q99504; A8K190; B4DIR7; B4DNZ7; O95463; Q8IVX7; Q99813

Background:

Eyes absent homolog 3 (EYA3) is a tyrosine phosphatase that plays a pivotal role in DNA repair by specifically dephosphorylating 'Tyr-142' of histone H2AX, facilitating the recruitment of DNA repair complexes. Its activity is crucial in distinguishing between apoptotic and repair responses to genotoxic stress. Beyond DNA repair, EYA3's function as a histone phosphatase underpins its involvement in transcription regulation during organogenesis, coactivating SIX family members and influencing myoblast precursor cell proliferation.

Therapeutic significance:

Understanding the role of Eyes absent homolog 3 could open doors to potential therapeutic strategies, particularly in enhancing DNA repair mechanisms and modulating gene expression during development.